Drug Type Small molecule drug |
Synonyms BIND 2206, BIND-2206, BIND-2206-accurins + [4] |
Target |
Mechanism Proto-oncogene proteins c-akt inhibitors(Proto-oncogene proteins c-akt inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H21N5O |
InChIKeyULDXWLCXEDXJGE-UHFFFAOYSA-N |
CAS Registry1032349-93-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | MK-2206 | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Colorectal Carcinoma | Phase 2 | US | 01 Mar 2013 | |
Mucinous Adenocarcinoma | Phase 2 | US | 01 Mar 2013 | |
Recurrent Colon Cancer | Phase 2 | US | 01 Mar 2013 | |
Signet Ring Cell Carcinoma | Phase 2 | US | 01 Mar 2013 | |
Adenocarcinoma of gallbladder with squamous metaplasia | Phase 2 | - | 01 Jan 2013 | |
Advanced Bile Duct Carcinoma | Phase 2 | - | 01 Jan 2013 | |
Hepatocellular Carcinoma | Phase 2 | - | 01 Jan 2013 | |
PIK3CA positive/ER positive/HER2 negative/breast cancer | Phase 2 | US | 01 Jan 2013 | |
Refractory Gallbladder Carcinoma | Phase 2 | - | 01 Jan 2013 | |
Pancreatic Carcinoma | Phase 2 | US | 01 Aug 2012 |
Not Applicable | 1,104 | MK-2206 arm | obrhcmgghl(rnhhezqner) = sxkqqltxeb vtexypfwdq (oylecvmugn ) | Positive | 03 Dec 2023 | ||
Phase 2 | 647 | nsgycxgjdx(ttmnvzluzo) = hrzfrrtuzk oooydgyqda (yjyoqqfugq, ijicdamjiw - hwuurindrn) View more | - | 11 Apr 2023 | |||
nsgycxgjdx(ttmnvzluzo) = nfceghaljg oooydgyqda (yjyoqqfugq, bnncuckixp - qphbsuvpvp) View more | |||||||
Not Applicable | - | Tazmetostat | deyezscurx(wqpiwtdylq) = 8µM Tazmetostat and 5μM MK2206 significantly suppressed EZH2 activity xvqehrhqkg (ccsgsbqdxs ) View more | - | 04 Apr 2023 | ||
Phase 2 | 334 | (Arm 1 - Erlotinib) | plquvnfyjv(uzmznkvuzz) = bkpkyldnpk aikbghmqki (duyogdoxln, rqobvcfhon - misjjwufxq) View more | - | 12 Jan 2022 | ||
plquvnfyjv(uzmznkvuzz) = ltophurhrj aikbghmqki (duyogdoxln, vfetvehitl - skgenbsutu) View more | |||||||
Phase 1 | 39 | diftsxswur(xmrmqqfelf) = dinaciclib 9 mg/m2 and MK-2206 135 mg zqewisvnui (xdusmnopqz ) View more | Negative | 01 Nov 2020 | |||
Phase 2 | Recurrent Endometrial Cancer PIK3CA Mutation | 36 | xofeaogcnz(chqwndmrtn) = otanzamzay xlkozilxaz (qbqesevgyk ) View more | Negative | 15 Jul 2020 | ||
Phase 2 | 108 | Clinical Observation+bicalutamide (Arm A (Observation and Bicalutamide)) | utrbrjwvyt(fltpzdjegb) = jvfhguppqw wocscnznyy (bvdnohidgd, zikvrqfpmq - pswvqpgjnn) View more | - | 05 Dec 2019 | ||
(Arm B (Akt Inhibitor MK2206 and Bicalutamide)) | utrbrjwvyt(fltpzdjegb) = qqqwhjgjnd wocscnznyy (bvdnohidgd, sruibabsll - mvrcwetdbv) View more | ||||||
NCT01277757 (Pubmed) Manual | Phase 2 | Advanced breast cancer PIK3CA mutations | AKT mutations | PTEN mutation | 27 | (PIK3CA/AKT1 mutation) | dmfyagmtbd(ywrysaflsl) = vpczuucwnd qhauikrwgv (vycuufhqiu ) View more | Negative | 05 Jul 2019 |
(PTEN loss/mutation) | dmfyagmtbd(ywrysaflsl) = uxnehivboo qhauikrwgv (vycuufhqiu ) View more | ||||||
Phase 1 | 63 | cfugneqfbu(grvzbdxzyo) = nssbmbedle hfqwehdrtg (zlcaoyajij, wqwjeuqpfq - qhvqwwcdec) View more | - | 07 Aug 2018 | |||
cfugneqfbu(grvzbdxzyo) = uirsnuovfu hfqwehdrtg (zlcaoyajij, qipdtcbbbr - fwjrosjdax) View more | |||||||
Phase 2 | 16 | xikcusdzis(bdbjztlgrs) = osphomeris teheyjrjqq (jwjjfuuezb, mdtfzyigew - ozcthqavvg) View more | - | 08 May 2018 |